Sergliflozin etabonate
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | none |
Identifiers | |
| |
CAS Number | 408504-26-7 |
PubChem (CID) | 9824918 |
IUPHAR/BPS | 4587 |
ChemSpider | 21234810 |
ChEMBL | CHEMBL450044 |
Chemical and physical data | |
Formula | C23H28O9 |
Molar mass | 448.463 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Sergliflozin etabonate (INN/USAN,[1][2] codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline. It did not undergo further development after phase II.
Method of action
Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3][4]
Chemistry
Etabonate refers to the ethyl carbonate group. The remaining structure, which is the active substance, is called sergliflozin.
References
- ↑ World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 59" (PDF). WHO Drug Information. 22 (1): 66.
- ↑ "Statement on a nonproprietary name adopted by the USAN council: Sergliflozin etabonate" (PDF). American Medical Association. Retrieved 2008-08-10.
- ↑ Katsuno K, Fujimori Y, Takemura Y, et al. (January 2007). "Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level". J Pharmacol Exp Ther. 320 (1): 323–30. doi:10.1124/jpet.106.110296. PMID 17050778.
- ↑ Prous Science: Molecule of the Month November 2007
This article is issued from Wikipedia - version of the 9/2/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.